Abstract
Hepatitis C virus (HCV) infection affects about 160 million people worldwide. It is treated with pegylatedinterferon (peg-IFN) and ribavirin, and in the case of patients affected by genotype 1, also with a protease inhibitor (telaprevir or boceprevir). Despite a good success rate, IFN-based combinations are contraindicated in several patients (e.g. decompensated cirrhosis, patients with psychiatric disorders, severe heart diseases or autoimmune disorders) and are associated with frequent adverse events that ultimately reduce their use. Numerous oral drugs are in an advanced phase of clinical development, and in some cases, in IFN-free combinations. This review focuses on preclinical and clinical data regarding daclatasvir (BMS-790052), which is a highly selective HCV NS5A replication complex inhibitor effective against HCV genotypes 1, 2, 3 and 4. In vitro data show that daclatasvir exerts a very potent antiviral effect against several HCV genotypes. Its pharmacokinetics is optimal and allows once-a-day oral administration. Its adverse event profile is good. Clinical data regarding its efficacy in combination with peg-IFN, ribavirin or other direct antiviral agents are impressive (rates of sustained virological response range between 60% and 100% in treatment-naïve patients). The only drawback of this drug appears to be a relatively low genetic barrier to resistance. In conclusion, daclatasvir, especially in combinations with other antiviral agents, is a very promising drug for the treatment of chronic hepatitis C.
Keywords: Combination therapy, daclatasvir, hepatitis C virus, Interferon-free, pegylated-interferon, polymerase inhibitors, resistance, ribavirin.
Current Medicinal Chemistry
Title:Daclatasvir: The First of a New Class of Drugs Targeted Against Hepatitis C Virus NS5A
Volume: 21 Issue: 12
Author(s): I. Gentile, F. Borgia, N. Coppola, A.R. Buonomo, G. Castaldo and G. Borgia
Affiliation:
Keywords: Combination therapy, daclatasvir, hepatitis C virus, Interferon-free, pegylated-interferon, polymerase inhibitors, resistance, ribavirin.
Abstract: Hepatitis C virus (HCV) infection affects about 160 million people worldwide. It is treated with pegylatedinterferon (peg-IFN) and ribavirin, and in the case of patients affected by genotype 1, also with a protease inhibitor (telaprevir or boceprevir). Despite a good success rate, IFN-based combinations are contraindicated in several patients (e.g. decompensated cirrhosis, patients with psychiatric disorders, severe heart diseases or autoimmune disorders) and are associated with frequent adverse events that ultimately reduce their use. Numerous oral drugs are in an advanced phase of clinical development, and in some cases, in IFN-free combinations. This review focuses on preclinical and clinical data regarding daclatasvir (BMS-790052), which is a highly selective HCV NS5A replication complex inhibitor effective against HCV genotypes 1, 2, 3 and 4. In vitro data show that daclatasvir exerts a very potent antiviral effect against several HCV genotypes. Its pharmacokinetics is optimal and allows once-a-day oral administration. Its adverse event profile is good. Clinical data regarding its efficacy in combination with peg-IFN, ribavirin or other direct antiviral agents are impressive (rates of sustained virological response range between 60% and 100% in treatment-naïve patients). The only drawback of this drug appears to be a relatively low genetic barrier to resistance. In conclusion, daclatasvir, especially in combinations with other antiviral agents, is a very promising drug for the treatment of chronic hepatitis C.
Export Options
About this article
Cite this article as:
Gentile I., Borgia F., Coppola N., Buonomo A.R., Castaldo G. and Borgia G., Daclatasvir: The First of a New Class of Drugs Targeted Against Hepatitis C Virus NS5A, Current Medicinal Chemistry 2014; 21 (12) . https://dx.doi.org/10.2174/0929867321666131228222215
DOI https://dx.doi.org/10.2174/0929867321666131228222215 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeted Drug Delivery for Cardiovascular and Cerebrovascular Diseases
Current Drug Targets Vitamin D Deficiency: Universal Risk Factor for Multifactorial Diseases?
Current Drug Targets Obstructive Sleep Apnea and Obesity
Current Respiratory Medicine Reviews The Development of Antibody-based Immunotherapy for Methamphetamine Abuse: Immunization, and Virus-Mediated Gene Transfer Approaches
Current Gene Therapy Contemporary Risk Assessment and Cardiovascular Outcomes in Peripheral Arterial Disease
Cardiovascular & Hematological Disorders-Drug Targets Review: Technegas - 99mTc-Metal Core Graphite Nanoparticles for Pulmonary Ventilation Imaging
Current Radiopharmaceuticals Apo A-1 Mimetic Peptides as Atheroprotective Agents in Murine Models
Current Drug Targets The Pivotal Role of Nitric Oxide: Effects on the Nervous and Immune Systems
Current Pharmaceutical Design Improvement of Bioactive Potential of Canavalia Beans of Coastal Sand Dunes by Solid-Substrate Fermentation Using Rhizopus oligosporus
Current Nutrition & Food Science HIV: A Raft-Targeting Approach for Prevention and Therapy Using Plant-Derived Compounds (Review)
Current Drug Targets Editorial [Concurrent Blood Pressure, Glycemic and Lipid Control for the Prevention of Vascular Complications of Type II Diabetes Mellitus: A Long Overdue Objective?]
Current Vascular Pharmacology Derivatives of 1,2,3,4-tetrahydroisoquinoline-7-carboxylic Acid as Novel Fibrinogen Receptor Antagonists
Medicinal Chemistry The Measurement of the QT Interval
Current Cardiology Reviews Lifestyle Factors and Endothelial Function
Current Vascular Pharmacology Biochemical Markers of Cardiovascular Damage from Tobacco Smoke
Current Pharmaceutical Design Exosomes: The Messengers of Health and Disease
Current Neuropharmacology Heme Oxygenase-Derived Carbon Monoxide Restores Vascular Function in Type 1 Diabetes
Drug Metabolism Letters The Effect of TNFα-Inhibitors on Cardiovascular Events in Patients with Rheumatoid Arthritis: An Updated Systematic Review of the Literature
Current Rheumatology Reviews The Coronin Family and Human Disease
Current Protein & Peptide Science Contrast Echocardiography: An Update on Clinical Applications
Current Pharmaceutical Design